PMC:7408073 / 102491-102922 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T11","span":{"begin":249,"end":254},"obj":"Body_part"},{"id":"T12","span":{"begin":255,"end":259},"obj":"Body_part"},{"id":"T13","span":{"begin":260,"end":265},"obj":"Body_part"},{"id":"T14","span":{"begin":266,"end":275},"obj":"Body_part"},{"id":"T15","span":{"begin":276,"end":282},"obj":"Body_part"},{"id":"T16","span":{"begin":283,"end":296},"obj":"Body_part"},{"id":"T17","span":{"begin":297,"end":302},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T203","span":{"begin":249,"end":254},"obj":"Body_part"},{"id":"T204","span":{"begin":255,"end":259},"obj":"Body_part"},{"id":"T205","span":{"begin":260,"end":265},"obj":"Body_part"},{"id":"T206","span":{"begin":266,"end":275},"obj":"Body_part"},{"id":"T207","span":{"begin":276,"end":282},"obj":"Body_part"},{"id":"T208","span":{"begin":283,"end":296},"obj":"Body_part"},{"id":"T209","span":{"begin":297,"end":302},"obj":"Body_part"}],"attributes":[{"id":"A203","pred":"uberon_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A204","pred":"uberon_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A205","pred":"uberon_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A206","pred":"uberon_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"A207","pred":"uberon_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A208","pred":"uberon_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"A209","pred":"uberon_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3532","span":{"begin":192,"end":196},"obj":"Gene"},{"id":"3533","span":{"begin":357,"end":361},"obj":"Gene"},{"id":"3535","span":{"begin":0,"end":3},"obj":"Gene"},{"id":"3540","span":{"begin":163,"end":171},"obj":"Species"},{"id":"3541","span":{"begin":422,"end":430},"obj":"Species"},{"id":"3547","span":{"begin":413,"end":421},"obj":"Disease"}],"attributes":[{"id":"A3532","pred":"tao:has_database_id","subj":"3532","obj":"Gene:59272"},{"id":"A3533","pred":"tao:has_database_id","subj":"3533","obj":"Gene:59272"},{"id":"A3535","pred":"tao:has_database_id","subj":"3535","obj":"Gene:4295"},{"id":"A3540","pred":"tao:has_database_id","subj":"3540","obj":"Tax:9606"},{"id":"A3541","pred":"tao:has_database_id","subj":"3541","obj":"Tax:9606"},{"id":"A3547","pred":"tao:has_database_id","subj":"3547","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T562","span":{"begin":413,"end":421},"obj":"Disease"}],"attributes":[{"id":"A562","pred":"mondo_id","subj":"T562","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T22","span":{"begin":181,"end":182},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T23","span":{"begin":249,"end":254},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T24","span":{"begin":249,"end":254},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T25","span":{"begin":249,"end":254},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T26","span":{"begin":249,"end":254},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T27","span":{"begin":255,"end":259},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T28","span":{"begin":255,"end":259},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T29","span":{"begin":260,"end":265},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T30","span":{"begin":260,"end":265},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T31","span":{"begin":266,"end":275},"obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"T32","span":{"begin":266,"end":275},"obj":"http://www.ebi.ac.uk/efo/EFO_0000834"},{"id":"T33","span":{"begin":276,"end":282},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T34","span":{"begin":276,"end":282},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T35","span":{"begin":276,"end":282},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T36","span":{"begin":283,"end":296},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T37","span":{"begin":297,"end":302},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T38","span":{"begin":297,"end":302},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"}],"text":"MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":297,"end":314},"obj":"http://purl.obolibrary.org/obo/GO_0007596"},{"id":"T4","span":{"begin":303,"end":314},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T500","span":{"begin":0,"end":431},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients."}